blue cross blue shield plans reverse course on glp-1 coverage Drops of Obesity Drugs Why we are changing coverage

Skin pigmentation and its control: From ultraviolet radiation to stem cells

Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo [4]

In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]

BPC-157 is a synthetic pentadecapeptide a chain of 15 amino acids derived from a protective protein naturally found in human gastric juice